Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease

BACKGROUND: Current guidelines recommend an oral anticoagulant (OAC) monotherapy in patients with nonvalvular atrial fibrillation (NVAF) and stable coronary artery disease (CAD) 1 year postpercutaneous coronary intervention (PCI). It might be possible to shorten the time for de-escalation from a dua...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukamachi, Daisuke, Okumura, Yasuo, Matsumoto, Naoya, Tachibana, Eizo, Oiwa, Koji, Ichikawa, Makoto, Haruta, Hironori, Nomoto, Kazumiki, Arima, Ken, Hirayama, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789898/
https://www.ncbi.nlm.nih.gov/pubmed/36619818
http://dx.doi.org/10.1155/2022/5905022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789898/
https://www.ncbi.nlm.nih.gov/pubmed/36619818
http://dx.doi.org/10.1155/2022/5905022

Ejemplares similares